Invloed van aminobifosfonaten en statinen op circulerende Vgamma9Vdelta2-T cellen.
Completed
- Conditions
- Ossaal gemetastaseerde maligniteitBone metastases of a malignant tumor
- Registration Number
- NL-OMON26533
- Lead Sponsor
- Prof. dr. H.M.W. Verheul, MD, PhDHead Department of Medical OncologyVU University Medical CenterDe Boelelaan 11171081 HV AmsterdamThe NetherlandsTel: +31 (0)20-4444321/300Fax: + 31 (0)20-4444079Email: h.verheul@vumc.nl
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Patients with an indication for intravenous treatment with an aminobisphosphonate because of bone metastases of a malignant tumor;
2. WHO 0, 1, 2 performance score.
Exclusion Criteria
1. WHO 3, 4 performance score;
2. Prior or current use of aminobisphosphonates;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Phenotypic (APC markers: CD1d, CD40, CD80, CD83, CD86, HLA-DR; activation/memory markers: CD25, CD27, CD45RA, CD45RO, CCR7) and functional (IFN-ã, TNF-á, granzyme B) changes in the circulating pool of Vy9Vd2-T cells;<br /><br>2. Occurrence of a febrile response.
- Secondary Outcome Measures
Name Time Method